Cutaneous leishmaniasis: successful treatment with itraconazole
| Autor: | Cristian Danielo, Javier Consigli, Verónica Gallerano, Andrés Guidi, Mariana Papa |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Itraconazole medicine.medical_treatment Mucocutaneous zone Antiprotozoal Agents Administration Oral Leishmaniasis Cutaneous Dermatology Severity of Illness Index Drug Administration Schedule Cutaneous leishmaniasis Amphotericin B medicine Animals Humans Chemotherapy Dose-Response Relationship Drug biology business.industry Leishmaniasis Middle Aged medicine.disease Leishmania biology.organism_classification Treatment Outcome Immunology Antimonial business Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Dermatology. 45:46-49 |
| ISSN: | 1365-4632 0011-9059 |
| Popis: | Background Leishmaniasis is a disease produced by several species of protozoa of the Leishmania genus. These protozoa are injected into the human bloodstream by sandflies. The symptomathology, either cutaneous, mucocutaneous or visceral, depends on the infective species and the immune status of the patient. Antimonial drugs are the mainstay treatment for all the clinical forms of the disease. Amphotericin B is the second-choice drug. Methods We report two clinical cases of cutaneous leishmaniasis treated with itraconazole. One case was a relapsing form unresponsive to conventional therapy. Results Both patients achieved fast resolution of their lesions with no secondary effects. Conclusions Itraconazole may be a valid option for the treatment of cutaneous leishmaniasis, mainly in those cases unresponsive to conventional drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text